Compare AbCellera Biologics Inc (ABCL) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dollar Tree, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Dollar Tree, Inc. trades at $124.28 (market cap $23.57B). The key difference: Dollar Tree, Inc. is far larger — about 10× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | DLTR | |
|---|---|---|
Market Cap | $2.35B | $23.57B |
Sector | Health | Health |
52-Week High | $8.12 | $141.21 |
52-Week Low | $2.78 | $85.04 |
Enterprise Value | $1.99B | $30.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Dollar Tree (DLTR) trades at $122.65, down 1.13% on the day, but maintains a bullish technical signal with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights a new $2.5 billion share repurchase authorization, signaling management confidence. Revenue for 2025 was $17.58 billion, though net income was impacted by a significant tax expense, resulting in a loss. Analyst consensus is bullish with a $130.70 price target, and institutional sentiment is positive amid evolving value retail strategies.
The outlook for DLTR is cautiously optimistic, driven by earnings momentum, share buybacks, and margin improvements. Key opportunities include multi-price strategy gains and cost controls, but risks involve traffic softness, inflationary pressures, and competitive threats. The stock's current valuation metrics, such as a P/E of 19.5, appear reasonable relative to growth prospects, though investors should monitor execution against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
